Osimertinib: A Game-Changer in Stage IV EGFR-Driven Lung Cancer
Lung cancer has a high mortality rate; however, treatment with tyrosine kinase inhibitors targeting specific molecular alterations has significantly improved the survival of patients with advanced or metastatic non-small cell lung carcinoma (NSCLC). EGFR mutations are present in approximately 15% o...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ordem dos Médicos
2025-04-01
|
| Series: | Acta Médica Portuguesa |
| Subjects: | |
| Online Access: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/22031 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|